Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Kenvue

The First New US Sunscreen Filter Since the 1990s Becomes Legal to Use on August 9, but Shelves Will Take Longer

Bemotrizinol clears US marketing on August 9, 2026. Products are expected later, though one major manufacturer has confirmed plans to use it.

Medical Daily

The New Tylenol with Naproxen Tablet Is Not the Dose Most Coverage Reported, and That Distinction Matters

FDA approved the first OTC acetaminophen-naproxen combination pill. The label warns against pairing it with other acetaminophen products.

Medical Daily

FDA Approves the First Over the Counter Tablet Combining Tylenol and Naproxen for 12 Hour Pain Relief

FDA-approved Tylenol with Naproxen, the first OTC combination of acetaminophen and naproxen sodium, for up to 12 hours of pain relief.

Medical Daily

From analysis to the latest developments in health,
read the most diverse news in one place.

The New Tylenol and Naproxen Pill Creates Two Different Ways to Double Up by Accident

The FDA approved the first OTC acetaminophen and naproxen combination pill. It creates two separate ways to accidentally exceed a daily limit.

Medical Daily

FDA approves new version of Tylenol with added ingredient

New fast-acting non-opioid drug will soon be available

The Independent UK

What Are Wall Street Analysts' Target Price for Kenvue Stock?

Kenvue has lagged the broader market over the past year, leaving analysts with a measured view on the stock.

Barchart

What to Expect From Kenvue’s Q2 2026 Earnings Report

Kenvue heads into its second-quarter earnings release with analysts projecting low double-digit EPS growth.

Barchart

Read news from The Economist, FT, and more,
with one subscription

Appeals Court Revives 500-Plus Tylenol Autism Lawsuits: What Pregnant Women Should Know About the Evidence

A federal appeals court revived 500+ Tylenol autism lawsuits on July 13, 2026. Medical societies still back acetaminophen in pregnancy. Here's what the evidence shows.

Medical Daily

US appeals court revives hundreds of lawsuits linking Tylenol to autism

IN FULL

The Independent UK

Judges allow lawsuit that ties Tylenol to autism to continue after it was dismissed for lack of ‘scientific evidence’

The move has revived more than 500 private lawsuits against Tylenol maker Kenvue

The Independent UK

Health officials sound the alarm over viral ‘Benadryl challenge’ after 5 kids hospitalized in San Diego

At least five kids were sent to Rady Children’s Hospital in San Diego, California, after attempting the challenge

The Independent UK

ASIA PACIFIC'S LEADING DENTAL BODY CALLS FOR A PREVENTION-FIRST SHIFT IN ORAL HEALTH, BACKED BY NEW GLOBAL EVIDENCE

SINGAPORE, May 25, 2026 /PRNewswire/ -- The Asia Pacific Dental Federation (APDF) has released The Power of Prevention: Evidence-Based Guidelines for Self-Oral Care, a landmark white paper setting out what effective daily oral care should look like and why it matters well beyond your teeth.

AAP

Ken Paxton wanted to limit forum shopping. Now lawyers say he’s improperly seeking favorable courts.

ProPublica and The Texas Tribune have identified at least 30 lawsuits filed by the attorney general over the past nine years that have a tenuous connection to the counties in which they were filed.

The Texas Tribune

Kenvue Stock: Is Wall Street Bullish or Bearish?

Kenvue has underperformed the broader market over the past year, and analysts remain skeptical about the stock’s prospects.

Barchart

Get all your
news in one place.

100's of premium titles.
One news app.

MarketBeat

Skip the 10-Year Bond? 3 Dividend Aristocrats to Consider Now

Three Dividend Aristocrats offer yields above the 10-year Treasury while delivering income growth and potential capital appreciation

International Business Times UK

Is Marmite Still British? £50bn Sale to US Giant McCormick Sparks Concern Over Recipe Changes and Price

Unilever agrees to merge its food business, including Marmite, with US spice maker McCormick in a deal worth £50bn, raising concerns over UK jobs and prices.

Fortune

Fortune Brands CEO never officially worked a day—but he’ll get $18.4 million after a massive leadership shakeup

The son-in-law of activist billionaire Nelson Peltz triggered the shakeup—and now he's getting a board seat and a say in who runs the company next

Barchart

How Is Kenvue’s Stock Performance Compared to Other Consumer Staple Stocks?

While recent performance trails the industry, Kenvue continues to retain measured analyst confidence and long-term relevance.

Get all your
news in one place.

100's of premium titles.
One news app.

Barchart

Kenvue Is Headed for a Merger Vote on January 29. How Should You Play KVUE Stock Here?

KVUE stock could gain 15% this week if the potential merger with Kimberly-Clark is approved by all major stakeholders.

Barchart

Kenvue Stock: Analyst Estimates & Ratings

As Kenvue has underperformed the broader market over the past year, Wall Street analysts maintain a cautious outlook about the stock’s prospects.

Barchart

Earnings Preview: What to Expect From Kenvue’s Report

Kenvue is gearing to release its fourth-quarter results shortly, and analysts expect its earnings to fall in low-double-digits.

MarketBeat

Insider Buying: Smart Money Just Spent +$100M on These 3 Stocks

Institutional insiders are placing big bets on DASH, KVUE, and KYMR. See how much is being spent on these three stocks and which investors are buying.

Barchart

Kenvue Stock: Is KVUE Underperforming the Consumer Defensive Sector?

As Kenvue has performed weaker than the consumer defensive sector over the past year, Wall Street analysts maintain a cautious outlook on the stock’s prospects.

MarketBeat

3 Smart Defensive Stocks for an Uneasy Market

Recession risks persist despite record market highs. Here are three defensive stocks—including PG, JNJ, and the DIA ETF—that can help protect your portfolio

Benzinga

Court Rejects Bid To Block Kenvue's $398 Million Shareholder Payout In Tylenol Safety Dispute

On Friday, a Texas judge declined to halt an upcoming shareholder payout by Texas Attorney General Ken Paxton to restrict Kenvue Inc.'s (NYSE:KVUE) handling and marketing of Tylenol amid ongoing litigation over the product's safety for pregnant women.

1 2 3 4 5

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Health and Human Services

298 stories

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.